PEG-P-INF alfa-2b: Completed Phase III enrollment

AOP completed enrollment of >260 patients in the open-label, European Phase III PROUD-PV trial comparing 50-500 ug subcutaneous ropeginterferon alfa-2b every other week vs. oral hydroxyurea once daily...